"Oncolytic Virotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Use of attenuated VIRUSES as ANTINEOPLASTIC AGENTS to selectively kill CANCER cells.
| Descriptor ID |
D050130
|
| MeSH Number(s) |
E02.095.601
|
| Concept/Terms |
Oncolytic Virotherapy- Oncolytic Virotherapy
- Oncolytic Virotherapies
- Virotherapies, Oncolytic
- Virotherapy, Oncolytic
- Oncolytic Virus Therapy
- Oncolytic Virus Therapies
- Therapies, Oncolytic Virus
- Therapy, Oncolytic Virus
- Virus Therapies, Oncolytic
- Virus Therapy, Oncolytic
|
Below are MeSH descriptors whose meaning is more general than "Oncolytic Virotherapy".
Below are MeSH descriptors whose meaning is more specific than "Oncolytic Virotherapy".
This graph shows the total number of publications written about "Oncolytic Virotherapy" by people in this website by year, and whether "Oncolytic Virotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 2 | 2 | 4 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 1 | 2 |
| 2022 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oncolytic Virotherapy" by people in Profiles.
-
TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy. J Immunother Cancer. 2022 05; 10(5).
-
The use of oncolytic virotherapy in the neoadjuvant setting. J Immunother Cancer. 2022 04; 10(4).
-
Modulation of the tumor microenvironment by armed vesicular stomatitis virus in a syngeneic pancreatic cancer model. Virol J. 2022 02 23; 19(1):32.
-
Pharmacological Inhibition of WEE1 Potentiates the Antitumoral Effect of the dl922-947 Oncolytic Virus in Malignant Mesothelioma Cell Lines. Int J Mol Sci. 2020 Oct 04; 21(19).
-
Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer. J Immunother Cancer. 2020 05; 8(1).
-
Chimeric tumor modeling reveals role of partial PDL1 expression in resistance to virally induced immunotherapy. J Immunother Cancer. 2019 01 16; 7(1):11.
-
Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy. Cancer Res. 2017 06 01; 77(11):2952-2963.
-
Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Mol Ther. 2016 Jun; 24(6):1150-1158.
-
STAT1 and NF-?B Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells. Mol Cancer Res. 2016 05; 14(5):482-92.
-
Changes in BAI1 and nestin expression are prognostic indicators for survival and metastases in breast cancer and provide opportunities for dual targeted therapies. Mol Cancer Ther. 2015 Jan; 14(1):307-14.